Patents by Inventor Alberto Visintin

Alberto Visintin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor H-Fc immunotheraphy
    Patent number: 10975131
    Abstract: Fusion proteins comprising human FH domains 18-20 (FH18-20) linked via an optional linker to IgG Fc, wherein the FH has mutation of D to G at position 1119 in domain 19; FHD1119G/Fc), and methods of use thereof, e.g., to treat pathogen infections.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: April 13, 2021
    Assignee: University of Massachusetts
    Inventors: Sanjay Ram, Douglas T. Golenbock, Alberto Visintin, Jutamas Shaughnessy
  • Factor H-Fc Immunotheraphy
    Publication number: 20180305425
    Abstract: Fusion proteins comprising human FH domains 18-20 (FH18-20) linked via an optional linker to IgG Fc, wherein the FH has mutation of D to G at position 1119 in domain 19; FHD1119G/Fc), and methods of use thereof, e.g., to treat pathogen infections.
    Type: Application
    Filed: October 27, 2016
    Publication date: October 25, 2018
    Inventors: Sanjay Ram, Douglas T. Golenbock, Alberto Visintin, Jutamas Shaughnessy
  • Toll-like receptor assays
    Patent number: 8124349
    Abstract: Methods of identifying compounds that modulate the interaction between a TLR and a molecule that interacts with the TLR by direct binding or by inclusion in a complex that associates with the TLR are described. Methods of identifying molecules that interact with a TLR are also described.
    Type: Grant
    Filed: January 6, 2006
    Date of Patent: February 28, 2012
    Assignee: University of Massachusetts
    Inventors: Eicke Latz, Alberto Visintin, Douglas T. Golenbock
  • Anti-pathogen immunoadhesins
    Patent number: 8080245
    Abstract: Chimeric molecules that include a pathogen recognition module derived from a pathogen binding domain of a pathogen recognition protein, e.g., a toll-like receptor (TLR), CD14, BPI, MD-2, scavenger receptors (SRs), surfactant proteins (SP), C-reactive protein (CRP), Mannan-binding lectin (MBL), or complement Clq globular binding domain, an optional linker, and an Fc portion of an antibody are described and are useful for, e.g., drug discovery and treatment of conditions related to TLR signaling.
    Type: Grant
    Filed: August 4, 2005
    Date of Patent: December 20, 2011
    Assignee: University of Massachusetts
    Inventors: Alberto Visintin, Douglas T. Golenbock
  • Toll-Like Receptor 9 Modulators
    Publication number: 20100291577
    Abstract: TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described.
    Type: Application
    Filed: May 25, 2010
    Publication date: November 18, 2010
    Applicant: UNIVERSITY OF MASSACHUSETTS
    Inventors: EICKE LATZ, ALBERTO VISINTIN, DOUGLAS T. GOLENBOCK
  • Toll-like receptor 9 modulators
    Patent number: 7723054
    Abstract: TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described.
    Type: Grant
    Filed: January 26, 2006
    Date of Patent: May 25, 2010
    Assignee: University of Massachusetts
    Inventors: Eicke Latz, Alberto Visintin, Douglas T. Golenbock
  • Anti-Pathogen Immunoadhesins
    Publication number: 20090208501
    Abstract: Chimeric molecules that include a pathogen recognition module derived from a pathogen binding domain of a pathogen recognition protein, e.g., a toll-like receptor (TLR), CD14, BPI, MD-2, scavenger receptors (SRs), surfactant proteins (SP), C-reactive protein (CRP), Mannan-binding lectin (MBL), or complement Clq globular binding domain, an optional linker, and an Fc portion of an antibody are described and are useful for, e.g., drug discovery and treatment of conditions related to TLR signaling.
    Type: Application
    Filed: August 4, 2005
    Publication date: August 20, 2009
    Inventors: Alberto Visintin, Douglas T. Golenbock
  • Methods of treating disorders associated with toll-like receptor 4 (TLR4) signalling
    Publication number: 20060241040
    Abstract: Described herein are methods and compositions for treating, preventing, and diagnosing disorders associated with TLR4 signalling, e.g., gram negative bacterial infection and sterile inflammations such as rheumatoid arthritis.
    Type: Application
    Filed: April 6, 2006
    Publication date: October 26, 2006
    Inventors: Alberto Visintin, Douglas Golenbock
  • Toll-like receptor 9 modulators
    Publication number: 20060127884
    Abstract: TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described.
    Type: Application
    Filed: January 26, 2006
    Publication date: June 15, 2006
    Inventors: Eicke Latz, Alberto Visintin, Douglas Golenbock
  • Toll-like receptor assays
    Publication number: 20060099650
    Abstract: Methods of identifying compounds that modulate the interaction between a TLR and a molecule that interacts with the TLR by direct binding or by inclusion in a complex that associates with the TLR are described. Methods of identifying molecules that interact with a TLR are also described.
    Type: Application
    Filed: January 6, 2006
    Publication date: May 11, 2006
    Inventors: Eicke Latz, Alberto Visintin, Douglas Golenbock
  • Toll-like receptor 9 modulators
    Publication number: 20050255451
    Abstract: TLR9 is localized to endoplasmic reticulum and upon stimulation with a TLR9 ligand, is transported to a tubular lysosomal compartment as is CpG-DNA. Furthermore, it is shown that TLR9 and CpG-DNA directly bind. It was also found that the MyD88 translocates in response to activation of TLR9-mediated signaling. Methods of identifying compounds that affect translocation and activity of TLR9 and MyD88 are described.
    Type: Application
    Filed: December 16, 2004
    Publication date: November 17, 2005
    Inventors: Eicke Latz, Alberto Visintin, Douglas Golenbock
  • Toll-like receptor assays
    Publication number: 20050208470
    Abstract: Methods of identifying compounds that modulate the interaction between a TLR and a molecule that interacts with the TLR by direct binding or by inclusion in a complex that associates with the TLR are described. Methods of identifying molecules that interact with a TLR are also described.
    Type: Application
    Filed: December 16, 2004
    Publication date: September 22, 2005
    Applicant: University of Massachusetts
    Inventors: Eicke Latz, Alberto Visintin, Douglas Golenbock